Noura El-Kattan, Mostafa A Ibrahim, Ahmed N Emam, Khaled Metwally, Fady Sayed Youssef, Nourelhuda Ahmed Nassar, Ahmed S Mansour
{"title":"Evaluation of the antimicrobial activity of chitosan- and curcumin-capped copper oxide nanostructures against multi-drug-resistant microorganisms.","authors":"Noura El-Kattan, Mostafa A Ibrahim, Ahmed N Emam, Khaled Metwally, Fady Sayed Youssef, Nourelhuda Ahmed Nassar, Ahmed S Mansour","doi":"10.1039/d4na00955j","DOIUrl":null,"url":null,"abstract":"<p><p>The emergence of multi-drug-resistant microorganisms presents a serious threat to infection control, for which new antimicrobial strategies are urgently needed. Herein, the antimicrobial activities of copper oxide nanoparticles capped with curcumin (Cur-CuO NPs) and copper oxide nanoparticles capped with chitosan (CS-CuO NPs) were investigated. They were prepared <i>via</i> the co-precipitation method. A total of 180 clinical ICU patients were found to have 70% Gram-negative and 30% Gram-positive isolates. Antimicrobial susceptibility testing indicated resistance of these isolates to 14 among the 21 tested antibiotics. Physicochemical properties of the curcumin-capped (Cur-CuO NPs) and chitosan-capped (CS-CuO NPs) copper oxide nanoparticles were identified using UV-vis spectroscopy, transmission electron microscopy (TEM), dynamic light scattering (DLS), zeta-potential (<i>ζ</i>), and Fourier transform infrared (FT-IR) spectroscopy. Cur-CuO- and CS-CuO-NPs exhibited potent antimicrobial efficacy, wherein CS-CuO NPs were found to possess a lower minimum inhibitory concentration (MIC) (3.9-15.6 μg mL<sup>-1</sup>) than Cur-CuO NPs (14.5-31.2 μg mL<sup>-1</sup>). Biocompatibility assay showed that Cur-CuO NPs were safer with an IC<sub>50</sub> dose of 74.17 μg mL<sup>-1</sup> than CS-CuO NPs with an IC<sub>50</sub> dose of 41.01 μg mL<sup>-1</sup>. Results revealed that the Cur-CuO- and CS-CuO-NPs have the potential to be safely used as effective antimicrobial agents in clinical applications at low concentrations (6.25-12.5 μg mL<sup>-1</sup>).</p>","PeriodicalId":18806,"journal":{"name":"Nanoscale Advances","volume":" ","pages":""},"PeriodicalIF":4.6000,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11962744/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nanoscale Advances","FirstCategoryId":"88","ListUrlMain":"https://doi.org/10.1039/d4na00955j","RegionNum":3,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}
引用次数: 0
Abstract
The emergence of multi-drug-resistant microorganisms presents a serious threat to infection control, for which new antimicrobial strategies are urgently needed. Herein, the antimicrobial activities of copper oxide nanoparticles capped with curcumin (Cur-CuO NPs) and copper oxide nanoparticles capped with chitosan (CS-CuO NPs) were investigated. They were prepared via the co-precipitation method. A total of 180 clinical ICU patients were found to have 70% Gram-negative and 30% Gram-positive isolates. Antimicrobial susceptibility testing indicated resistance of these isolates to 14 among the 21 tested antibiotics. Physicochemical properties of the curcumin-capped (Cur-CuO NPs) and chitosan-capped (CS-CuO NPs) copper oxide nanoparticles were identified using UV-vis spectroscopy, transmission electron microscopy (TEM), dynamic light scattering (DLS), zeta-potential (ζ), and Fourier transform infrared (FT-IR) spectroscopy. Cur-CuO- and CS-CuO-NPs exhibited potent antimicrobial efficacy, wherein CS-CuO NPs were found to possess a lower minimum inhibitory concentration (MIC) (3.9-15.6 μg mL-1) than Cur-CuO NPs (14.5-31.2 μg mL-1). Biocompatibility assay showed that Cur-CuO NPs were safer with an IC50 dose of 74.17 μg mL-1 than CS-CuO NPs with an IC50 dose of 41.01 μg mL-1. Results revealed that the Cur-CuO- and CS-CuO-NPs have the potential to be safely used as effective antimicrobial agents in clinical applications at low concentrations (6.25-12.5 μg mL-1).